ConductScience.org, home

Paper1733554

Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors.

Knapp DW and 4 others. Cancer Chemother Pharmacol, 1992. Cited by 96 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Papers, record 1733554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1733554

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1992
PubMed
Publication types
Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
96
iCite
Relative citation ratio, by iCite
3.5
iCite
Revised in PubMed
2019-08-27
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Knapp DWD W
2Richardson RCR C
3Bottoms GDG D
4Teclaw RR
5Chan TCT C

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Dog DiseasesMajor topic
NeoplasmsMajor topic
PiroxicamMajor topic
Animals
Dogs
Drug Administration Schedule
Drug Evaluation
Female
Male

Source PubMed

References17

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17,400,257Analysis of piroxicam in plasma by high-performance liquid chromatography.J Chromatogr1980https://conductscience.org/library/papers/7400257PubMed
23,318,750Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response.Arch Intern Med1987https://conductscience.org/library/papers/3318750PubMed
312,765Piroxicam, a novel anti-inflammatory agent.Arzneimittelforschung1976https://conductscience.org/library/papers/12765PubMed
46,345,166Piroxicam--a literature review of new results from laboratory and clinical studies.Eur J Rheumatol Inflamm1983https://conductscience.org/library/papers/6345166PubMed
56,113,108Metabolism of piroxicam by laboratory animals.Drug Metab Dispos1981https://conductscience.org/library/papers/6113108PubMed
64,981,040Mastocytoma and gastroduodenal ulceration. Gastric and duodenal ulcers in dogs with mastocytoma.Pathol Vet1969https://conductscience.org/library/papers/4981040PubMed
76,691,775Piroxicam-induced renal disease.Arch Intern Med1984https://conductscience.org/library/papers/6691775PubMed
83,652,039Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development.Cancer Res1987https://conductscience.org/library/papers/3652039PubMed
96,861,813Pharmacokinetics of piroxicam in man.Eur J Rheumatol Inflamm1983https://conductscience.org/library/papers/6861813PubMed
106,509,432Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea.Cancer Lett1984https://conductscience.org/library/papers/6509432PubMed
116,640,513The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat.Cancer Lett1983https://conductscience.org/library/papers/6640513PubMed
123,166,075Piroxicam inhibits the growth of an adenocarcinoma isograft in Fischer rats.J Surg Res1988https://conductscience.org/library/papers/3166075PubMed
132,109,653
Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet.
Cancer Res1990https://conductscience.org/library/papers/2109653PubMed
143,099,048Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil.J Natl Cancer Inst1986https://conductscience.org/library/papers/3099048PubMed
156,363,936Renal syndromes associated with nonsteroidal antiinflammatory drugs.N Engl J Med1984https://conductscience.org/library/papers/6363936PubMed
162,819,706Prevention and treatment of primary intestinal tumors in rats by piroxicam.Cancer Res1989https://conductscience.org/library/papers/2819706PubMed
172,736,316[Regression and slowing of the growth of human pulmonary metastases induced by piroxicam, an inhibitor of prostaglandin synthesis].Bull Cancer1989https://conductscience.org/library/papers/2736316PubMed

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 96 citations.

PMIDTitleJournalYearIn PapersSource
42,319,213Clinical Remission of an Unresectable Presumptive Haemangiosarcoma in a Dog Treated With Toceranib, Piroxicam, and Propranolol: A Case Report.Vet Med Sci2026https://conductscience.org/library/papers/42319213PubMed
40,351,767Identification of metastasis-associated protein 1 (MTA1) as a new molecular marker for canine urothelial carcinoma.Front Vet Sci2025https://conductscience.org/library/papers/40351767PubMed
38,922,022Multimodal Blockade of the Renin-Angiotensin System in the Treatment of Cancer in Dogs Has Mild Adverse Effects in Some Dogs.Vet Sci2024https://conductscience.org/library/papers/38922022PubMed
37,624,316Meloxicam in Combination with Mitoxantrone or Vinblastine as First-Line Treatment for Non-Resectable Urothelial Cell Carcinoma in Dogs.Vet Sci2023https://conductscience.org/library/papers/37624316PubMed
37,377,896Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.Cancer Res Commun2023https://conductscience.org/library/papers/37377896PubMed
35,893,776Canine Gastric Cancer: Current Treatment Approaches.Vet Sci2022https://conductscience.org/library/papers/35893776PubMed
35,665,759Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy.Sci Rep2022https://conductscience.org/library/papers/35665759PubMed
33,534,961Prevalence of gastrointestinal lesions in dogs chronically treated with nonsteroidal anti-inflammatory drugs.J Vet Intern Med2021https://conductscience.org/library/papers/33534961PubMed
32,255,906In-vitro effects of taurolidine alone and in combination with mitoxantrone and/or piroxicam on canine transitional cell carcinoma.Can J Vet Res2020https://conductscience.org/library/papers/32255906PubMed
32,039,002Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.Front Oncol2019https://conductscience.org/library/papers/32039002PubMed
29,445,618Comparative oncology: Integrating human and veterinary medicine.Open Vet J2018https://conductscience.org/library/papers/29445618PubMed
28,781,660Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells.Oncol Lett2017https://conductscience.org/library/papers/28781660PubMed
27,784,990Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer.Drug Des Devel Ther2016https://conductscience.org/library/papers/27784990PubMed
27,773,993Toxico-Neurological Effects of Piroxicam in Monogastric Animals.J Exp Neurosci2016https://conductscience.org/library/papers/27773993PubMed
26,566,160Dogs as a Model for Cancer.Annu Rev Anim Biosci2016https://conductscience.org/library/papers/26566160PubMed
23,531,445Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo.Cancer Prev Res (Phila)2013https://conductscience.org/library/papers/23531445PubMed
23,117,797Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.J Biomed Opt2012https://conductscience.org/library/papers/23117797PubMed
19,436,636Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.Can Vet J2009https://conductscience.org/library/papers/19436636PubMed
18,980,687Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma.J Exp Clin Cancer Res2008https://conductscience.org/library/papers/18980687PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1733554

GET https://conductscience.org/api/papers/v1/1733554/authors